Literatur
-
1
Camma C, Giunta M, Rosselli M, Cottone M.
Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables.
Gastroenterology.
1997;
113
1465-1473
-
2
Feagan B G, Fedorak R N, Irvine E J, Wild G, Sutherland L, Steinhart A H, Greenberg G R, Koval J, Wong C J, Hopkins M, Hanauer S B, McDonald J W.
A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators.
N Engl J Med.
2000;
342
1627-1632
-
3
Feagan B G, Rochon J, Fedorak R N, Irvine E J, Wild G, Sutherland L, Steinhart A H, Greenberg G R, Gillies R, Hopkins M. et al .
Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators.
N Engl J Med.
1995;
332
292-297
-
4
Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer S B, Irvine E J, Jewell D P, Rachmilewitz D, Sachar D B, Sandborn W J, Sutherland L R.
A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
Inflamm Bowel Dis.
2000;
6
8-15
-
5
Hanauer S B, Feagan B G, Lichtenstein G R, Mayer L F, Schreiber S, Colombel J F, Rachmilewitz D, Wolf D C, Olson A, Bao W, Rutgeerts P.
Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial.
Lancet.
2002;
359
1541-1549
-
6
Hanauer S B, Stromberg U.
Oral Pentasa in the treatment of active Crohn’s disease: A meta-analysis of double-blind, placebo-controlled trials.
Clin Gastroenterol Hepatol.
2004;
2
379-388
-
7
Hoffmann J C, Zeitz M, Bischoff S C, Brambs H J, Bruch H P, Buhr H J, Dignass A, Fischer I, Fleig W, Folsch U R, Herrlinger K, Hohne W, Jantschek G, Kaltz B, Keller K M, Knebel U, Kroesen A J, Kruis W, Matthes H, Moser G, Mundt S, Pox C, Reinshagen M, Reißmann A, Riemann J, Rogler G, Schmiegel W, Schölmerich J, Schreiber S, Schwandner O, Selbmann H K, Stange E F, Utzig M, Wittekind C.
Diagnosis and therapy of ulcerative colitis: Results of an Evidence Based Consensus Conference of the German Society of Digestive and Metabolic Diseases and the Competence Network Inflammatory Bowel Diseases.
Z Gastroenterol.
2004;
42
979-983
-
8
Lichtiger S, Present D H, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S.
Cyclosporine in severe ulcerative colitis refractory to steroid therapy.
N Engl J Med.
1994;
330
1841-1845
-
9
Marshall J K, Irvine E J.
Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis.
Aliment Pharmacol Ther.
1995;
9
293-300
-
10
Pearson D C, May G R, Fick G, Sutherland L R.
Azathioprine for maintaining remission of Crohn’s disease.
Cochrane Database Syst Rev.
2000;
CD000067
-
11
Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C.
Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease.
Cochrane Database Syst Rev.
2000;
CD000545
-
12
Schwab M, Herrlinger K, Schaeffeler E, Stange E F.
Therapie chronisch entzündlicher Darmerkrankungen mit Azathioprin, 6-Mercaptopurin und 6-Thioguanin. Klinisch-pharmakologische Aspekte.
Dtsch Med Wochenschr.
2003;
128
378-385
-
13
Sutherland L, Roth D, Beck P, May G, Makiyama K.
Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis.
Cochrane Database Syst Rev.
2000;
CD000544
-
14
Sutherland L, Roth D, Beck P, May G, Makiyama K.
Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis.
Cochrane Database Syst Rev.
2000;
CD000543
Prof. Dr. med. Eduard Stange
Abteilung Innere Medizin 1, Zentrum für Innere Medizin, Robert-Bosch-Krankenhaus
Auerbachstraße 110
70376 Stuttgart
Phone: 0711/81013406
Fax: 0711/81013793
Email: Eduard.Stange@rbk.de
